MAVENIR
30.9.2021 15:02:04 CEST | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced its next-generation Operations Support System (ngOSS) , a new addition to the MAVscale platform.
The new solution brings together a powerful combination of Artificial Intelligence (AI), Analytics, Automation, and Orchestration, backed by Mavenir’s experience delivering telecom network solutions to allow Communication Service Providers (CSPs) to deploy ngOSS in their 4G networks today, while at the same time preparing to fully realize the potential of 5G capabilities through intelligent network operations.
By enhancing network performance, Mavenir’s ngOSS enables CSPs to improve the overall customer experience, lower operating expenses (OPEX), and reduce the risk of manual errors more prevalent in legacy OSS systems.
The end-to-end, cloud-native automation framework is built based on TM Forum’s Open Digital Architecture (ODA) and OpenAPIs that uses enhanced AI and Machine Learning (ML) models to deliver advanced network performance. Engineered with a microservices-based architecture, Mavenir's ngOSS solution simplifies large, legacy, monolithic systems into smaller, autonomous components that offer intelligence, insights, and network control. A more open, automated network is necessary to break legacy vendor lock-in while driving innovation for 5G use cases.
Mavenir is an OSS vendor with 4G/5G and mobile core/Radio Access Network (RAN) expertise, and in-depth understanding of orchestrating telecommunications workloads required for enabling advanced 5G capabilities, including network slicing, which translates directly into efficiencies for the CSPs.
“As CSPs advance toward automation, next-generation OSS will be a critical component to enable the network of the future,” said Kuntal Chowdhury, SVP and GM of AI and Analytics at Mavenir. “Using advanced AI and ML models to enhance network performance will help CSPs deliver superior customer experience, while scalable automation reduces manual tasks to lower maintenance costs and reduces the risk of human error. Mavenir’s ngOSS solution allows CSPs to break open the network and take advantage of Open APIs to increase agility and innovation, introduce new services, and monetize 5G with rapid service velocity.”
Key capabilities of Mavenir’s ngOSS include:
- Service Fulfillment and Orchestration – Service Order Management integrates with the Business Support System (BSS) layer using Open APIs to deliver dynamic order creation, support complex workflow creation, and offer complete visibility & management into service order execution. Service Orchestration provides a complete network automation solution, including Service Design, 5G Slice Management, and Network Service Orchestration.
- Data Management – Mavenir’s Provisioning and Activation function is radically different from the traditional provisioning offerings from legacy vendors. It elevates provisioning to a whole new level by offering Provisioning-as-a-Service on any cloud, from any vendor, on any domain approach. In addition, Mavenir’s Active Inventory collects, maintains, and exposes a federated real-time view of available network resources and services from across multiple cloud and vendor environments.
- Service Assurance and AI Operations (AIOps) – Mavenir Service Assurance and AIOps platform addresses CSP’s operational challenges by providing end-to-end visibility into the network, enabling an open network by integrating with any cloud, any vendor, and any technology domain, and performing critical AIOps functions, such as AI-driven predictive alarm correlation, ML-assisted Ticket Analysis, and auto Root Cause Analysis (RCA), resulting in increased productivity, shorter Mean Time To Repair (MTTR), and OPEX savings.
- Domain Controllers – Mavenir’s Non-Real-Time RAN Intelligent Controller (RIC) is a containerized application that uses advanced machine learning algorithms to optimize RAN performance and train ML models using long term RAN data for dynamic and adaptive policy and control. Mavenir’s Network Subnet Slice Management Function (NSSMF) is an open, cloud-native, and vendor-agnostic function that plays a crucial role in 5G slice management as it does the last-mile connections necessary to configure a slice.
Supporting documents:
Mavenir ngOSS webpage
Mavenir ngOSS solution brief
About Mavenir
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry’s only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210930005144/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
